Clearside Biomedical Signs Agreement with Santen Pharmaceutical for Eye Disease Treatment
Friday, November 08, 2024
Clearside Biomedical announced a collaboration agreement between its Asia-Pacific partner, Arctic Vision, and Santen Pharmaceutical.
Clearside's proprietary SCS® injection approach delivers medication to the back of the eye, a location crucial for treating sight-threatening diseases. The SCS Microinjector®, a patented device, injects a wide range of medications into the targeted area, potentially improving treatment effectiveness and reducing side effects.
UME is a fluid build-up in the macula (responsible for central vision) caused by uveitis, an inflammatory eye condition. It's a leading cause of vision loss, affecting millions globally.
This agreement between Arctic Vision and Santen has the potential to bring ARVN001 to UME patients in Asia-Pacific, offering a new treatment option.
The agreement focuses on ARVN001 (XIPERE® in the US), a treatment for uveitic macular edema (UME) and other eye conditions under development. Arctic Vision gains rights to commercialise ARVN001 in mainland China (excluding Taiwan, Hong Kong and Macau).
This deal strengthens Clearside's suprachoroidal delivery platform, already utilised by major pharmaceutical companies such as Bausch + Lomb, AbbVie and Santen.
Source: clearsidebio.com
